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OBJECTIVEdMany studies of diabetes have examined risk factors at the time of diabetes
diagnosis instead of considering the lifetime burden of adverse risk factor levels. We examined
the30-year cardiovascular disease (CVD) riskfactor burdenthat participantshave up to thetime
of diabetes diagnosis.
RESEARCH DESIGN AND METHODSdAmong participants free of CVD, incident di-
abetes cases (fasting plasma glucose $126 mg/dL or treatment) occurring at examinations 2
through 8 (1979–2008) of the Framingham Heart Study Offspring cohort were age- and sex-
matched 1:2 to controls. CVD risk factors (hypertension, high LDL cholesterol, low HDL cho-
lesterol, high triglycerides, obesity) were measured at the time of diabetes diagnosis and at time
points 10, 20, and 30 yearsprior. Conditionallogisticregressionwas usedto compare risk factor
levels at each time point between diabetes cases and controls.
RESULTSdWe identiﬁed 525 participants with new-onset diabetes who were matched to
1,049 controls (mean age, 60 years; 40% women). Compared with those without diabetes,
individuals who eventually developed diabetes had higher levels of hypertension (odds ratio
[OR], 2.2; P = 0.003), high LDL (OR, 1.5; P = 0.04), low HDL (OR, 2.1; P = 0.0001), high
triglycerides(OR,1.7;P=0.04),andobesity(OR,3.3;P,0.0001)attimepoints30yearsbefore
diabetes diagnosis. After further adjustment for BMI, the ORs for hypertension (OR, 1.9; P =
0.02) and low HDL (OR, 1.7; P = 0.01) remained statistically signiﬁcant.
CONCLUSIONSdCVDriskfactorsare increasedup to 30 years beforediagnosis of diabetes.
TheseﬁndingshighlighttheimportanceofalifecourseapproachtoCVDriskfactoridentiﬁcation
among individuals at risk for diabetes.
Diabetes Care 36:1590–1596, 2013
M
any studies of diabetes have fo-
cused on cardiovascular disease
(CVD) risk factors at the time of
diabetes diagnosis. However, it is likely
that CVD risk factors that accompany
diabetes, including obesity, hypertension,
and dyslipidemia, are increased decades
before the clinical onset of diabetes.
Two previous studies have suggested
that individuals who develop diabetes
may have increased CVD risk factor bur-
den up to 15 years before their diabetes
diagnosis, relative to those who do not
have development of diabetes (1,2) How-
ever, one limitation of these studies is
that 15 years before diabetes diagnosis
may not be a long enough time range to
capturetheearly middle-ageperiodwhen
risk factor intervention might be more
feasible.
A better understanding of the life-
long risk factor burden that participants
bear before the time of diabetes diagnosis
can enable us to identify those at greatest
risk for ultimate development of CVD.
Thus, the objective of our study was to
examine CVD risk factor burden during
the time period of up to 30 years before
diabetes diagnosis among individuals
who did and did not develop diabetes.
RESEARCH DESIGN AND
METHODS
Study sample
The study sample for this project was
derived from individuals participating in
the Framingham Heart Study (3–6). The
Framingham Heart Study started in 1948
with the enrollment of 5,209 participants,
aged 28–62 years, into the Original cohort
(3,4).The Offspring cohort wasinitiated in
1971 with the enrollment of 5,124 off-
spring of the Original cohort participants
and their spouses (5). Individuals in the
Offspring cohort underwent medical ex-
aminations approximately every 4 years.
Written informed consent was provided
by all of the participants and the study has
been approved by the Boston University
Medical Center Institutional Review Board.
The study was conducted using a
prospective nested case-control design.
Cases were deﬁned asany individual with
newly diagnosed type 2 diabetes at Off-
spring examinations 2 through 8. Each
diabetescasewasmatchedtotwocontrols
(if available) by sex and 2-year age group
atthestudyexaminationatwhichthecase
was diagnosed with diabetes. Controls
were selected using risk set sampling, in
which all individuals who did not have
diabetes at the time the case received
diagnosis were eligible for selection
(7,8). Using this method, individuals
who were controls during the earlier
timeperiodswereeligibletobecomecases
at subsequent examinations. Cases with
prevalent CVD at the time of diabetes
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ORIGINAL ARTICLEdiagnosisandcontrolswhohad prevalent
CVD at the time they were matched to a
case were excluded, because our ultimate
goal was to identify individuals with fu-
ture risk of CVD. Type 2 diabetes was de-
ﬁned as having a fasting plasma glucose
$126 mg/dL or treatment with insulin or
an oral hypoglycemic agent (9). For one
case, there was only one available control
that met the matching criteria, resulting
in a ﬁnal sample size of 525 cases and
1,029 controls.
CVD risk factor measurements
The following CVD risk factors were mea-
suredduring eachofthe eightexamination
cycles: systolic blood pressure; diastolic
bloodpressure;LDLcholesterol;HDLcho-
lesterol; triglycerides; and BMI. For the
present analysis, CVD risk factor measure-
mentswereobtainedatthetimeofdiabetes
diagnosisandattimepoints10,20,and30
years previously, when available. The risk
factor measurement during the examina-
tion closest to each of the time points was
selected.
Systolic blood pressure and diastolic
blood pressure were measured twice by a
study physician and theaverage of thetwo
measurements was taken. Hypertension
was deﬁned as systolic blood pressure
$140 mmHg or diastolic blood pressure
$90 mmHg or current use of antihyper-
tensive treatment. HDL cholesterol and
triglycerides were measured after an over-
night fast. High LDL cholesterol was de-
ﬁned as LDL level $130 mg/dL or
treatment with a lipid-lowering medi-
cation. Low HDL was deﬁned as HDL
,40 mg/dL for men and ,50 mg/dL for
women. A high triglyceride level was de-
ﬁnedasa measurementof $150mg/dLor
treatment with a lipid-lowering medica-
tion. Use of antihypertensive treatment or
lipid-lowering medication was self-
reported at each examination. Hyperten-
sion control was deﬁned as the proportion
ofparticipantswithhypertensionwhohad
blood pressure ,140/90 mmHg. LDL
control was deﬁned as the proportion of
participants with high LDL cholesterol
who had LDL levels ,130 mg/dL. Height
andweightweremeasuredusingstandard-
ized protocols. The BMI was calculated by
dividingweightinkilogramsbythesquare
ofheightinmeters.Obesitywasdeﬁnedas
having a BMI $30 kg/m
2.
Statistical analysis
Conditional logistic regression models
were used to calculate odds ratios (ORs)
and 95% conﬁdence intervals for the
association between each CVD risk factor
and future diabetes status at each point in
time. The primary model accounted for
theageandsexmatching.Allmodelswere
additionally adjusted for BMI. Condi-
tional logistic regression also was used
to calculate P values for comparisons be-
tween the diabetes case and control
groups to formally test differences in
risk factors. All analyses were conducted
using SAS 9.2 (Cary, NC). P , 0.05 was
considered statistically signiﬁcant.
RESULTSdA total of 525 diabetes ca-
ses and 1,049 age- and sex-matched con-
trols were derived from examinations 2
through 8 (1979–2005). Of these study
participants, 516 cases and 1,030 con-
trols had risk factor measurements avail-
able 10 years before diabetes diagnosis,
417 cases and 835 controls had measure-
ments available 20 years before diabetes
diagnosis,and176casesand350controls
had measurements available 30 years be-
fore diabetes diagnosis.
Characteristics of the diabetes cases
and controls are presented in Table 1.
Overall, at the time of diabetes diagnosis,
cases had higher blood pressure, triglycer-
ides, and BMI, and had lower LDL choles-
terol and HDL cholesterol than the
controls.Casesalsohadahigherprevalence
of lipid and hypertension treatment than
the controls. At time points 10, 20, and
30 years before diabetes diagnosis, the
cases had higher levels of blood pressure,
triglycerides,andBMI,andhadlowerlev-
els of HDL cholesterol than the controls.
(Table 1 and Fig. 1) The cases also had
higher levels of LDL cholesterol than the
controls. Levels of treatment for hyper-
tension and lipids also were higher for
thecasesatalltimepointsbeforediabetes
diagnosis.
Table 2 shows the logistic regression
model results for the categorical CVD risk
factors. At the time of diabetes diagnosis,
cases were more likely to have hyperten-
sion,highLDLcholesterol,lowHDLcho-
lesterol, high triglycerides, obesity,
hypertension treatment, and lipid treat-
ment as compared with the controls after
adjustmentforage,sex, andcalendaryear
of diabetes diagnosis. For example, indi-
viduals with newly diagnosed diabetes
had a three-fold increased odds of having
hypertension compared with those with-
out diabetes. After further adjustment for
BMI, individuals with newly diagnosed
diabetes had an approximate two-fold in-
creased odds of having hypertension
compared with those who did not
develop diabetes. For all risk factors ex-
cept high LDL cholesterol, further adjust-
ment for BMI measured at the time of
diabetes diagnosis resulted in a statisti-
cally signiﬁcant, although attenuated,
OR.
Attime points10yearsbeforediabetes
diagnosis, the diabetes cases were more
likelytohavehigherlevelsofhypertension,
low HDL cholesterol, high triglycerides,
hypertension treatment, lipid treatment,
and obesity relative to those who did not
go on to develop diabetes. For example,
caseswithnewlydiagnoseddiabeteshad
2.4-times the odds of having hyper-
tension 10 years before diagnosis
as compared with controls. Further ad-
justment for BMI measured 10 years be-
forediabetesdiagnosisresultedinanOR
of 1.8. Overall, further adjustment for
BMI attenuated the ORs, but they re-
mained statistically signiﬁcant for all
factors except lipid treatment.
At 20 years before diabetes diagnosis,
the diabetes cases were more likely to
have hypertension, low HDL cholesterol,
high triglycerides, hypertension treat-
ment, and obesity as compared with
individualswhodidnotdevelopdiabetes.
These differences persisted for low HDL
cholesterol and high triglycerides after
adjustment for BMI measured 20 years
before diagnosis.
Finally, individuals who developed
diabetes also were more likely to have
hypertension, high LDL cholesterol, low
HDL cholesterol, high triglycerides, and
obesity at time points up to 30 years
before the development of diabetes. After
further adjustment for BMI measured 30
years before diagnosis, the differences
between cases and controls remained
statistically signiﬁcant for hypertension
and low HDL cholesterol.
The logistic regression model results
for the continuous CVD risk factors are
presentedinTable3.Similartothecategor-
ical outcomes, individuals who developed
diabetes had higher levels of all cardiovas-
cular risk factors at the time of diabetes di-
agnosis. Individuals who ultimately
developed diabetes also had higher lev-
els of blood pressure, LDL cholesterol,
triglycerides, and BMI, and had lower
levels of HDL cholesterol at time points
up to 30 years before the time of diagno-
sis. After further adjustment for BMI
measured 30 years before diabetes diag-
nosis, individuals who went on to de-
velop diabetes had lower absolute
levels of HDL cholesterol and higher
levels of triglycerides.
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Preis and AssociatesCONCLUSIONS
Principal ﬁndings
We examined the midlife CVD risk factor
burden among individuals who did and
did not develop diabetes at time points 10,
20,and30yearsbeforediagnosis.Thereare
four main ﬁndings from our study. First,
individuals with newly diagnosed diabetes
have an increased burden of CVD risk
factorsatthetimeoftheirdiagnosisrelative
to age- and sex-matched controls. Second,
theoverallprevalenceoftreatmentforboth
elevatedblood pressure and lipidsislow at
the time of diabetes diagnosis. Third, we
demonstrated that this increased CVD risk
factor burden among individuals who go
onto develop diabetes exists at time points
upto30yearsbeforediagnosis.Fourth,the
increased risk factor burden among indi-
viduals who develop diabetes remained
after adjustment for BMI. Taken together,
these results highlight that diabetes is a life
course disease and underscores the point
Table 1dComparison of risk factor levels between diabetes cases and controls over time in the Framingham Heart Study
Risk factor
Timing of risk factor measurement
At time of diabetes
diagnosis
;10 Years before
diabetes diagnosis
;20 Years before
diabetes diagnosis
;30 Years before
diabetes diagnosis
Control Case Control Case Control Case Control Case
(n =1 , 0 4 9 ) ( n =5 2 5 ) ( n =1 , 0 3 0 ) ( n =5 1 6 ) ( n =8 3 5 ) ( n =4 1 7 ) ( n =3 5 0 ) ( n = 176)
Continuous characteristics,
mean (SD)
Age (years) 60 (10) 60 (10) 50 (10) 50 (10) 42 (9) 42 (9) 36 (8) 36 (8)
Calendar year of
examination visit 1995 (8) 1995 (8) 1985 (8) 1985 (8) 1978 (6) 1978 (6) 1974 (2) 1974 (2)
Systolic blood pressure
(mmHg) 129 (18) 136 (17) 125 (17) 133 (16) 122 (16) 127 (15) 120 (14) 122 (14)
Diastolic blood pressure
(mmHg) 76 (10) 79 (11) 79 (10) 83 (10) 79 (10) 83 (10) 77 (9) 79 (10)
LDL cholesterol (mg/dL) 126 (34) 121 (35) 133 (34) 135 (36) 130 (35) 136 (35) 121 (35) 127 (31)
HDL cholesterol (mg/dL) 52 (16) 43 (13) 51 (15) 43 (13) 51 (15) 45 (14) 52 (15) 47 (13)
Log triglycerides (mg/dL) 4.7 (0.5) 5.1 (0.6) 4.6 (0.6) 4.9 (0.6) 4.4 (0.7) 4.6 (0.6) 4.2 (0.7) 4.4 (0.7)
BMI (kg/m
2) 27.4 (4.7) 31.7 (6.0) 26.4 (4.2) 30.1 (5.2) 25.7 (4.1) 28.5 (4.9) 25.0 (3.8) 27.0 (4.5)
Continuous characteristics,
median (25th percentile,
75th percentile)
Triglycerides (mg/dL) 108 165 94 136 77 108 67 90
(76, 157) (112, 235) (65, 143) (97, 196) (53, 121) (68, 163) (45, 104) (54, 134)
Categorical characteristics, n (%)
Women 466 (44.4) 233 (44.4) 455 (44.2) 229 (44.4) 362 (43.4) 182 (43.7) 154 (44.0) 79 (44.9)
Decade of examination visit
2000–2 0 0 8 2 7 5( 2 6 . 2 ) 1 4 4( 2 7 . 4 ) 2( 0 . 2 ) 2( 0 . 4 ) 0( 0 . 0 ) 0( 0 . 0 ) 0( 0 . 0 ) 0( 0 . 0 )
1990–1999 512 (48.8) 252 (48.0) 280 (27.2) 148 (28.7) 7 (0.8) 2 (0.5) 0 (0.0) 0 (0.0)
1980–1989 260 (24.8) 126 (24.0) 533 (51.8) 267 (51.7) 342 (41.0) 179 (42.9) 28 (8.0) 10 (5.7)
1970–1979 2 (0.2) 3 (0.6) 215 (20.9) 99 (19.2) 486 (58.2) 236 (56.6) 322 (92.0) 166 (94.3)
Hypertension 468 (44.6) 363 (69.1) 313 (30.5) 253 (49.2) 178 (21.4) 130 (31.3) 41 (11.7) 38 (22.0)
High LDL cholesterol* 564 (54.9) 294 (59.8) 524 (53.0) 281 (57.6) 388 (47.8) 199 (50.6) 125 (35.7) 78 (44.3)
Low HDL cholesterol† 332 (31.7) 317 (61.6) 346 (34.3) 301 (59.5) 262 (31.6) 225 (54.9) 102 (29.1) 81 (46.0)
High triglycerides‡ 419 (39.9) 357 (68.9) 241 (23.8) 230 (45.4) 130 (15.7) 126 (30.7) 42 (12.0) 32 (18.2)
Hypertension treatment 292 (27.9) 251 (47.8) 121 (11.8) 113 (22.1) 39 (4.7) 34 (8.2) 2 (0.6) 5 (2.9)
Lipid treatment 173 (16.5) 129 (24.6) 33 (3.2) 28 (5.5) 2 (0.2) 2 (0.4) 0 (0.0) 0 (0.0)
BMI category
$30 kg/m
2 263 (25.2) 283 (54.7) 172 (16.8) 226 (44.2) 116 (13.9) 142 (34.1) 33 (9.4) 33 (18.8)
25.0–29.9 kg/m
2 451 (43.2) 180 (34.8) 443 (43.2) 202 (39.5) 328 (39.4) 180 (43.2) 130 (37.1) 85 (48.3)
,25 kg/m
2 330 (31.6) 54 (10.4) 410 (40.0) 83 (16.2) 389 (46.7) 95 (22.8) 187 (53.4) 58 (33.0)
Fasting plasma glucose
$126 mg/dL or diabetes
treatment 0 (0.0) 525 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
100–125 mg/dL 354 (33.8) 0 (0.0) 110 (10.7) 180 (34.9) 34 (4.1) 33 (7.9) 0 (0.0) 0 (0.0)
,100 mg/dL 592 (56.4) 0 (0.0) 431 (41.8) 95 (18.4) 185 (22.2) 74 (17.8) 0 (0.0) 0 (0.0)
Missing 103 (9.8) 0 (0.0) 489 (47.5) 241 (46.7) 616 (73.8) 310 (74.3) 350 (100.0) 176 (100.0)
*LDL $130 mg/dL or lipid treatment. †,40 mg/dL in men and ,50 mg/dL in women. ‡.150 mg/dL or lipid treatment.
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CVD risk factor proﬁles and diabetesthatCVDriskassociatedwithdiabetesdoes
not begin at the time of clinical diabetes
diagnosis.
In the context of the current
literature
Two previous studies have examined the
prevalence of midlife CVD risk factors
a m o n gi n d i v i d u a l sw h og oo nt od e v e l o p
diabetes (1,2). One study examined the
CVD risk factor proﬁles of 1,847 individ-
uals aged 40–79 years from Rancho Ber-
nardo, California, who were free of
diabetes and impaired fasting blood glu-
coseatbaselinein1972–1974(2).Afteran
average of 12 years of follow-up (range,
10–15 years; 1984–1987), individuals
who went on to develop diabetes had
higher levels of blood pressure, BMI, fast-
ing plasma glucose, and triglycerides at
the baseline examination when compared
with those who had normal fasting
plasma glucose levels at the end of the
follow-up period. Similar trends were
Figure 1dComparison of mean systolic blood pressure (A), BMI (B), LDL cholesterol (C), HDL cholesterol (D), and triglycerides (E) between
diabetes cases and matched controls at time points before diabetes diagnosis.
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Preis and Associatesseen among individuals who developed
impaired fasting plasma glucose at the
end of follow-up compared with individ-
uals who did not develop either diabetes
or impaired fasting glucose.
In a study of 614 Mexican Americans
from the San Antonio Heart Study (mean
age, 41–48 years at baseline) who were
free of diabetes at their baseline visit in
1979–1982, those who developed diabe-
tes after 8 years of follow-up had higher
baseline levels of total cholesterol, LDL
cholesterol, triglycerides, fasting plasma
glucose, BMI, and blood pressure, and
had lower levels of HDL cholesterol than
the participants who did not develop di-
abetes (1). These results persisted after
adjustment for baseline levels of BMI
and fasting plasma glucose. Our study is
consistent with previous studies showing
that individuals who go on to develop di-
abeteshavemodestlyhigherCVDriskfac-
tors levels up to three decades before
diagnosis. We found that individuals
with diabetes had lower LDL levels than
the controls at the time of diagnosis, pos-
sibly because of the greater prevalence of
lipid treatment among diabetes cases.
Lookingatthetimeperiodsupto30years
previously, this trend is reversed where
the LDL levels are higher among individ-
uals who eventually develop diabetes.
Our results from the current study ex-
pand on the current literature by
examining a longer time period of up to
30 years before clinical diabetes diagnosis
and by using more contemporary data.
Additionally,theparticipantsinourstudy
were slightly younger, having a mean age
of 36 years at time points ;30 years be-
fore diabetes diagnosis, allowing us to
examine a longer time range.
Biological mechanisms
Individualswhohaveelevatedriskfactors
earlyinlifehaveanincreasedriskofCVD.
For example,a study of 1,017 young men
(mean age, 22 years) found that higher
levels of total cholesterol in early adult-
hood were associated with increased risk
of coronary heart disease and CVD mor-
tality after 30 years of follow-up (10).
Early life CVD risk factor levels also
h a v eb e e ns h o w nt ob ea s s o c i a t e dw i t h
higher levels of coronary artery calcium,
a preclinical form of coronary heart dis-
ease (11,12). The importance of early-life
levels of CVD risk factors also was re-
cently underscored in an analysis of risk
factor levels for the prediction of elevated
coronary artery calcium, which showed
that early-life risk factors were more
strongly related as compared with con-
temporary risk factors (11). Autopsy
studies of adolescents and young adults
suggest that atherosclerotic plaques can
be found among individuals as young as
15 years old (13). Our data suggest that
diabetesfollowsasimilarpatterninwhich
the disease begins early in life with the
presence of elevated CVD risk factors.
Implications
Once clinically diagnosed with diabetes,
many guidelines suggest aggressive risk
factor management, particularly for gly-
cemic control, hypertension, dyslipide-
mia, and smoking cessation (14–17). In
addition, therapeutic lifestyle manage-
ment may include counseling regarding
weight reduction, increasing physical
Table 2dORs of diabetes by categorical CVD risk factors in the Framingham Heart Study
Outcome
At time of diabetes
diagnosis ;10 Years before diagnosis ;20 Years before diagnosis ;30 Years before diagnosis
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Hypertension
Model 1 3.02 (2.40–3.80) ,0.0001 2.41 (1.91–3.04) ,0.0001 1.76 (1.33–2.32) ,0.0001 2.18 (1.31–3.64) 0.003
Model 1 + BMI 2.34 (1.82–3.02) ,0.0001 1.80 (1.40–2.31) ,0.0001 1.19 (0.88–1.61) 0.26 1.85 (1.08–3.14) 0.02
High LDL cholesterol*
Model 1 1.21 (0.97–1.51) 0.09 1.24 (0.99–1.55) 0.07 1.15 (0.90–1.47) 0.28 1.51 (1.02–2.25) 0.04
Model 1 + BMI 1.11 (0.87–1.42) 0.39 1.16 (0.91–1.48) 0.23 1.06 (0.82–1.38) 0.65 1.29 (0.86–1.94) 0.23
Low HDL cholesterol†
Model 1 3.68 (2.92–4.63) ,0.0001 2.88 (2.30–3.60) ,0.0001 2.70 (2.11–3.46) ,0.0001 2.11 (1.44–3.09) 0.0001
Model 1 + BMI 2.56 (1.99–3.27) ,0.0001 2.20 (1.73–2.80) ,0.0001 2.04 (1.57–2.66) ,0.0001 1.67 (1.11–2.50) 0.01
High triglycerides‡
Model 1 3.60 (2.85–4.56) ,0.0001 2.84 (2.24–3.60) ,0.0001 2.47 (1.85–3.29) ,0.0001 1.71 (1.02–2.86) 0.04
Model 1 + BMI 2.78 (2.16–3.57) ,0.0001 2.20 (1.71–2.84) ,0.0001 1.85 (1.37–2.51) ,0.0001 1.35 (0.79–2.30) 0.28
Hypertension
treatment
Model 1 2.63 (2.08–3.33) ,0.0001 2.22 (1.66–2.98) ,0.0001 1.92 (1.16–3.18) 0.01 5.32 (1.02–27.83) 0.05
Model 1 + BMI 2.02 (1.56–2.61) ,0.0001 1.72 (1.25–2.36) 0.001 1.50 (0.87–2.56) 0.14 5.38 (1.02–28.31) 0.05
Lipid treatment
Model 1 1.97 (1.46–2.67) ,0.0001 1.85 (1.08–3.19) 0.03 1.84 (0.26–13.14) 0.54
Model 1 + BMI 1.77 (1.27–2.47) 0.0008 1.51 (0.84–2.72) 0.16 2.52 (0.34–18.71) 0.37
BMI category
Model 1
$30 kg/m
2 7.01 (4.96–9.90) ,0.0001 7.03 (1.81–3.35) ,0.0001 5.66 (3.98–8.05) ,0.0001 3.27 (1.83–5.84) ,0.0001
25.0–29.9 kg/m
2 2.59 (1.83–3.66) ,0.0001 2.47 (1.81–3.35) ,0.0001 2.58 (1.89–3.54) ,0.0001 2.25 (1.46–3.47) 0.0002
,25 kg/m
2 1.00 (Referent) 1.00 (Referent) 1.00 (Referent) 1.00 (Referent)
Model 1 adjusts for age, sex, and calendar year of diabetes diagnosis. *LDL $130 mg/dL or lipid treatment. †,40 mg/dL in men and ,50 mg/dL in women. ‡.150
mg/dL or lipid treatment.
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CVD risk factor proﬁles and diabetesactivity, and improved nutrition (15).
However, our data suggest that CVD
risk factor elevation is present well before
the time of clinical diabetes diagnosis.
Therefore, waiting to aggressively inter-
vene on CVD risk factors at the time of
diabetes diagnosis may mean the loss of
important clinical opportunities to re-
duce the ultimate life-long burden of
CVD risk. This also may explain why it
is difﬁcult to achieve major beneﬁts in
CVD risk reduction among individuals
with diabetes by focusing on glucose con-
trol alone (18). It has been shown that
intensive management of risk factors
among individuals with diabetes resulted
in lower mortality rates as compared with
standard therapy regimens (19). How-
ever, this ﬁnding has not been conﬁrmed
in subsequent larger studies (20,21). Our
ﬁndings suggest that it may be more im-
portanttofocusonadverseriskfactorlev-
els earlier in life, before diabetes is
present.
Our results are particularly notable
for the increased levels of BMI that ante-
date diabetes onset at all points in time,
with an increased prevalence of obesity of
two-fold to three-fold higher in those
destined to develop diabetes as compared
with controls at each time point. Because
obesity is an important risk factor for the
development of hypertension, dyslipide-
mia, and diabetes, these results highlight
the importance of aggressive weight man-
agementthroughtheentirelifecourseasa
means to ultimately reduce the burden of
diabetes, concomitant CVD risk factors,
and ultimately CVD (16,22). However, it
is also important to acknowledge that ad-
justment of our main results for BMI did
not completely attenuate the observed as-
sociations, suggesting that measures of
BMI alone may not completely explain
the risk. It is possible that differences in
bodycomposition,whichmaynotbecap-
tured by BMI, may be more important
than overall adiposity.
Strengths and limitations
The strengths of our study include the
long follow-up period of risk factor mea-
surement as well as the availability of
contemporarydata. Risk factordata were
carefullymeasuredinastandardizedway
across 30 years of our study. Participants
were primarily younger adults at the
time of their ﬁrst study examination, al-
lowing us to generalize our data back to
a wide age range. Finally, we were able
to follow-up study participants to when
theywereameanof60years,allowingus
to ascertain who was ultimately destined
to develop diabetes. Our study is limited
bytheall-whitecompositionofthestudy
population, which may limit generaliz-
ability to other ethnic or racial groups.
Additionally, although we had a long
duration of data, we did not have true
life-long data for the individuals in our
study. Because we used a nested case-
controldesign,wedidnothavecomplete
data for all of the participants for the 30
years before their diabetes diagnoses.
Our main results were adjusted for BMI;
however, we were unable to adjust for
other adiposity measurements, such as
waist circumference or visceral fat, be-
cause they were not available at all ex-
amination cycles. Overall, participants
who went on to develop diabetes had
more adverse risk factor proﬁles at every
time point than those who did not de-
velop diabetes. However, it is important
to note the majority of these participants
did not have elevated lipid or blood
pressure levels ;30 years before diagno-
sis.Ourstudywasnotabletoidentifythe
determinants of the “residual risk” that
these participants have.
Table 3dORs of diabetes per unit increase of continuous CVD risk factors in the Framingham Heart Study
At time of diabetes
diagnosis ;10 Years before diagnosis ;20 Years before diagnosis ;30 Years before diagnosis
Outcome OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Systolic blood pressure
(per 10 mmHg)
Model 1 1.26 (1.19–1.34) ,0.0001 1.36 (1.27–1.46) ,0.0001 1.27 (1.17–1.38) ,0.0001 1.13 (0.99–1.30) 0.07
Model 1 + BMI 1.21 (1.13–1.29) ,0.0001 1.25 (1.16–1.35) ,0.0001 1.14 (1.04–1.24) 0.005 1.04 (0.90–1.21) 0.56
Diastolic blood pressure
(per 10 mmHg)
Model 1 1.41 (1.26–1.58) ,0.0001 1.71 (1.52–1.93) ,0.0001 1.55 (1.36–1.77) ,0.0001 1.35 (1.08–1.68) 0.008
Model 1 + BMI 1.27 (1.12–1.44) 0.0002 1.45 (1.27–1.65) ,0.0001 1.27 (1.10–1.47) 0.001 1.15 (0.91–1.46) 0.23
LDL cholesterol
(per 10 mg/dL)
Model 1 0.96 (0.92–0.99) 0.009 1.02 (0.99–1.06) 0.17 1.06 (1.02–1.10) 0.002 1.06 (1.00–1.12) 0.07
Model 1 + BMI 0.94 (0.91–0.98) 0.004 1.01 (0.98–1.05) 0.47 1.04 (1.01–1.09) 0.02 1.03 (0.97–1.10) 0.32
HDL cholesterol
(per 10 mg/dL)
Model 1 0.57 (0.51–0.63) ,0.0001 0.61 (0.55–0.67) ,0.0001 0.65 (0.59–0.73) ,0.0001 0.73 (0.62–0.85) ,0.0001
Model 1 + BMI 0.66 (0.59–0.73) ,0.0001 0.71 (0.64–0.79) ,0.0001 0.74 (0.66–0.83) ,0.0001 0.80 (0.68–0.95) 0.009
Log triglycerides (mg/dL)
Model 1 4.09 (3.26–5.15) ,0.0001 3.51 (2.81–4.38) ,0.0001 2.16 (1.76–2.65) ,0.0001 1.67 (1.25–2.25) 0.0006
Model 1 + BMI 3.12 (2.45–3.96) ,0.0001 2.72 (2.16–3.42) ,0.0001 1.71 (1.38–2.12) ,0.0001 1.43 (1.06–1.93) 0.02
BMI (kg/m
2)
Model 1 1.18 (1.15–1.21) ,0.0001 1.19 (1.16–1.22) ,0.0001 1.16 (1.12–1.19) ,0.0001 1.13 (1.07–1.18) ,0.0001
Model 1 + BMI
Model 1 adjusts for age, sex, and calendar year of diabetes diagnosis.
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Preis and AssociatesConclusion
CVD risk factors are increased at the time
of diabetes diagnosis and up to 30 years
before the diagnosis of diabetes. These
ﬁndings suggest that diabetes should be
considered a life course disease and that
treatment and control of risk factors
should begin early in life rather than at
t h et i m eo fd i a b e t e sd i a g n o s i s .
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